Pasar al contenido principal

ANALISIS DE AISLADOS CLINICOS DE LEISHMANIA INFANTUM PROCEDENTES DE FALLO TERAPEUTICO: BUSQUEDA DE MARCADORES DE RESISTENCIA.

SAF2015-68042-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Drug resistance and treatment failure in leishmaniasis: A 21st century challenge

  • Ponte-Sucre, Alicia
  • Gamarro, Francisco
  • Dujardin, J. C.
  • Barrett, Michael P.
  • López-Vélez, Rogelio
  • García-Hernández, Raquel
  • Pountain, Andrew W.
  • Mwenechanya, Roy
  • Papadopoulou, Barbara
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including the global HIV/AIDS epidemic with its accompanying impact on the immune system. Pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis since the first half of the 20th century, but the last 10 to 20 years have witnessed an increase in clinical resistance, e.g., in North Bihar in India. In this review, we discuss the meaning of “resistance” related to leishmaniasis and discuss its molecular epidemiology, particularly for Leishmania donovani that causes visceral leishmaniasis. We also discuss how resistance can affect drug combination therapies. Molecular mechanisms known to contribute to resistance to antimonials, amphotericin B, and miltefosine are also outlined., Research reported in this publication was supported by the Canadian Institutes of Health Research operating grant MOP-12182 awarded to BP; the Spanish Grant Proyecto de Excelencia, Junta de Andalucía Ref. CTS-7282 awarded to FG; the Spanish Grant SAF2015-68042-R awarded to FG; the Wellcome Trust (104111/Z/14/Z) awarded to MPB; and the Alexander von Humboldt Foundation, Germany awarded to APS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei

  • Pham, ThanhTruc
  • Walden, Madeline
  • Butler, Christopher
  • Díaz-González, Rosario
  • Pérez-Moreno, Guiomar
  • Ceballos-Pérez, Gloria
  • Gómez-Pérez, Veronica
  • García-Hernández, Raquel
  • Zecca, Henry
  • Krakoff, Emma
  • Kopec, Brian
  • Ichire, Ogar
  • Mackenzie, Caden
  • Pitot, Marika
  • Ruiz-Pérez, Luis Miguel
  • Gamarro, Francisco
  • González-Pacanowska, Dolores
  • Navarro, M.
  • Dounay, Amy B.
In 2014, a published report of the high-throughput screen of>42,000 kinase inhibitors from GlaxoSmithKline against T. brucei identified 797 potent and selective hits. From this rich data set, we selected NEU-0001101 (1) for hit-to-lead optimization. Through our preliminary compound synthesis and SAR studies, we have confirmed the previously reported activity of 1 in a T. brucei cell proliferation assay and have identified alternative groups to replace the pyridyl ring in 1. Pyrazole 24 achieves improvements in both potency and lipophilicity relative to 1, while also showing good in vitro metabolic stability. The SAR developed on 24 provides new directions for further optimization of this novel scaffold for anti-trypanosomal drug discovery., Boettcher Foundation's Webb-Waring Biomedical Research Program; Boettcher Collaboration Grant; Research Corporation Cottrell College Science Award; National Institute of Allergy and Infectious Diseases (US):R01AI114685; Ministerio de Economia, Industria y Competitividad (España) SAF2015-71444-P; SAF2015-68042-R; SAF2016-79957-R; Junta de Andalucia CTS-7282; Subdireccion General de Redes y Centros de Investigacion Cooperativa (RICET) RD16/0027/0019, DG-P RD16/0027/0014; NSF-MRI CHE-1429567, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Leishmania LABCG1 and LABCG2 transporters are involved in virulence and oxidative stress: Functional linkage with autophagy

  • Manzano, José Ignacio
  • Perea, A.
  • León-Guerrero, D.
  • Campos-Salinas, Jenny
  • Piacenza, L.
  • Castanys, Santiago
  • Gamarro, Francisco
Background: The G subfamily of ABC (ATP-binding cassette) transporters of Leishmania include 6 genes (ABCG1-G6), some with relevant biological functions associated with drug resistance and phospholipid transport. Several studies have shown that Leishmania LABCG2 transporter plays a role in the exposure of phosphatidylserine (PS), in virulence and in resistance to antimonials. However, the involvement of this transporter in other key biological processes has not been studied. Methods: To better understand the biological function of LABCG2 and its nearly identical tandem-repeated transporter LABCG1, we have generated Leishmania major null mutant parasites for both genes (ΔLABCG1-2). NBD-PS uptake, infectivity, metacyclogenesis, autophagy and thiols were measured. Results: Leishmania major ΔLABCG1-2 parasites present a reduction in NBD-PS uptake, infectivity and virulence. In addition, we have shown that ΔLABCG1-2 parasites in stationary phase growth underwent less metacyclogenesis and presented differences in the plasma membrane's lipophosphoglycan composition. Considering that autophagy is an important process in terms of parasite virulence and cell differentiation, we have shown an autophagy defect in ΔLABCG1-2 parasites, detected by monitoring expression of the autophagosome marker RFP-ATG8. This defect correlates with increased levels of reactive oxygen species and higher non-protein thiol content in ΔLABCG1-2 parasites. HPLC analysis revealed that trypanothione and glutathione were the main molecules accumulated in these ΔLABCG1-2 parasites. The decrease in non-protein thiol levels due to preincubation with buthionine sulphoximide (a γ-glutamylcysteine synthetase inhibitor) restored the autophagy process in ΔLABCG1-2 parasites, indicating a relationship between autophagy and thiol content. Conclusions: LABCG1-2 transporters from Leishmania could be considered as phosphatidylserine and non-protein thiol transporters. They probably accomplish transportation in conjunction with other molecules that are involved in oxidative stress, autophagy, metacyclogenesis and infectivity processes. The overall conclusion is that LABCG1-2 transporters could play a key role in Leishmania cell survival and infectivity., This work was supported by the Spanish Grants SAF2015-68042-R (to S.C. and F.G.), SAF2012-34267 (to F.G.), by the Proyecto de Excelencia, Junta de Andalucia, Ref. CTS-7282 (to F.G.) and by FEDER funds from the EU to S.C. and F.G. A. Perea was a student of the PhD program “Biochemistry and Molecular Biology” of the University of Granada (Spain) and was supported by a fellowship for predoctoral contracts for PhD training from the Ministerio de Economia y Competitividad (in charge of Project SAF2012-34267).